Kate Therapeutics (KateTx) is a patient-focused biotechnology company developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined muscle and heart diseases. The company is applying novel technology platforms that directly address the key limitations of current gene therapies, including tissue-specific delivery and gene regulation. These breakthroughs have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies.

Biotechnology

Medical Devices

Therapeutics

Kate Therapeutics

Kevin Forrest

Eric Wang

Aislinn Puga

Nathan Jones

Mark Fielden

Sharif Tabebordbar

Christopher Kurtz

The Clinical Operations team at Kate Therapeutics plays a pivotal role in the design, implementation, and management of clinical trials for AAV-based gene therapies. They ensure compliance with regulatory standards, oversee trial logistics, and collaborate with cross-functional teams to streamline the development process, ultimately aiming to advance innovative treatments for genetically defined muscle and heart diseases.

Clinical Operations

Research and Development

Leadership Team

Clinical Operations

About

Team members

Other teams at Kate Therapeutics

Research and Development

Leadership Team